Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC37A4 | O43826 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 3/20 | 0.39 |
| ▸ | PPARA | Q07869 | 2/20 | 0.38 |
| ▸ | CYSLTR2 | Q9NS75 | 2/20 | 0.37 |
| ▸ | CYSLTR1 | Q9Y271 | 2/20 | 0.37 |
| ▸ | POLM | Q9NP87 | 1/20 | 0.36 |
| ▸ | POLK | Q9UBT6 | 1/20 | 0.36 |
| ▸ | POLL | Q9UGP5 | 1/20 | 0.36 |
| ▸ | POLH | Q9Y253 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5587415 | 0.92 | PPARG (0.41) | SLC37A4PPARGPPARACYSLTR2CYSLTR1 | |
| SCHEMBL5589479 | 0.92 | PPARG (0.41) | SLC37A4PPARGPPARACYSLTR2CYSLTR1 | |
| SCHEMBL5588889 | 0.92 | PPARG (0.41) | SLC37A4PPARGPPARACYSLTR2CYSLTR1 | |
| SCHEMBL5588682 | 0.92 | PPARG (0.41) | SLC37A4PPARGPPARACYSLTR2CYSLTR1 | |
| SCHEMBL5588173 | 0.92 | PPARG (0.41) | SLC37A4PPARGPPARACYSLTR2CYSLTR1 | |
| SCHEMBL5586664 | 0.92 | PPARG (0.41) | SLC37A4PPARGPPARACYSLTR2CYSLTR1 | |
| SCHEMBL5586906 | 0.90 | SLC37A4 (0.41) | SLC37A4PPARGPPARACYSLTR2CYSLTR1 | |
| SCHEMBL5590296 | 0.89 | SLC37A4 (0.52) | SLC37A4PPARGPPARACYSLTR2CYSLTR1 | |
| SCHEMBL5589027 | 0.86 | PPARG (0.38) | SLC37A4PPARGPPARACYSLTR2CYSLTR1 | |
| SCHEMBL5589529 | 0.84 | KDM4E (0.36) | SLC37A4PPARGPPARACYSLTR2CYSLTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7247687-B2 | Late transition metal catalysts for olefin polymerization and oligomerization | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2007-07-24 | — | — | US | disclosed |
| EP-1521758-B1 | LATE TRANSITION METAL CATALYSTS FOR OLEFIN POLYMERIZATION AND OLIGOMERIZATION | EXXONMOBIL CHEM PATENTS INC (US) | 2006-05-24 | — | — | EP | disclosed |
| US-20060047094-A1 | Late transition metal catalysts for olefin polymerization and oligomerization | EXXONMOBIL CHEMICAL PATENTS INC. | 2006-03-02 | — | — | US | disclosed |
| EP-1521758-A1 | LATE TRANSITION METAL CATALYSTS FOR OLEFIN POLYMERIZATION AND OLIGOMERIZATION | Exxonmobil Chemical Patents Inc. (US) | 2005-04-13 | — | — | EP | disclosed |
| WO-2004007509-A1 | LATE TRANSITION METAL CATALYSTS FOR OLEFIN POLYMERIZATION AND OLIGOMERIZATION | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060047094-A1 | Late transition metal catalysts for olefin polymerization and oligomerization | MLX, LOX, LMTK3 | SLC37A4 2424/4885PPARG 3592/4885PPARA 2921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.